DIA 2013 49th Annual Meeting
Click here to go to the previous page
Research Advances for Rare Diseases and Orphan Products
Track
:
Track 17: Rare/Orphan Diseases
Program Code:
222
Date:
Tuesday, June 25, 2013
Time:
8:00 AM to 9:30 AM
EST
Location:
257AB
CHAIR
:
Peter L. Saltonstall, (SCHSUP), President and CEO, National Organization For Rare Disorders (NORD), United States
SPEAKER
(S):
Marshall Summar, MD (SPKSUP), Chief, Genetics and Metabolism, Children's National Medical Center, United States Russell J. Teagarden, (SPKSUP), Senior Vice President, Medical and Scientific Affairs, National Organization For Rare Disorders (NORD), United States
Description
Research into new orphan drugs has grown substantially in recent years. In 2012, a third of the drugs approved by the FDA had orphan designation. This session will examine the current research efforts and discuss the role of the patient community, the FDA, the NIH and the drug industry in research priorities and challenges. Included will be the role of patient registries and natural histories. This session is hosted by the National Organization for Rare Disorders (NORD).
This session is a part of:
This session is a part of: